ACCORD BIOPHARMA

Serial Number 97298517
Registration 7592997
700

Registration Progress

Application Filed
Mar 7, 2022
Under Examination
Approved for Publication
Sep 10, 2024
Published for Opposition
Sep 10, 2024
Registered
Dec 10, 2024

Trademark Image

ACCORD BIOPHARMA

Basic Information

Serial Number
97298517
Registration Number
7592997
Filing Date
March 7, 2022
Registration Date
December 10, 2024
Published for Opposition
September 10, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Dec 10, 2024
Registration
Registered
Classes
005 044

Rights Holder

Accord BioPharma, Inc.

03
Address
1009 Slater Road, Suite 210B
Durham, NC 27703

Ownership History

Accord BioPharma, Inc.

Original Applicant
03
Durham, NC

Accord BioPharma, Inc.

Owner at Publication
03
Durham, NC

Accord BioPharma, Inc.

Original Registrant
03
Durham, NC

Legal Representation

Attorney
Michele K. Robichaux

USPTO Deadlines

Next Deadline
1806 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20241210)
Due Date
December 10, 2030
Grace Period Ends
June 10, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

34 events
Date Code Type Description Documents
Feb 17, 2025 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Feb 17, 2025 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Feb 17, 2025 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Dec 10, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Dec 10, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Sep 10, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Sep 10, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Aug 21, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Aug 6, 2024 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
May 3, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
May 3, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
May 3, 2024 ERFR I TEAS REQUEST FOR RECONSIDERATION RECEIVED Loading...
Feb 1, 2024 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Loading...
Feb 1, 2024 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Loading...
Nov 8, 2023 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED Loading...
Nov 8, 2023 GNFR O FINAL REFUSAL E-MAILED Loading...
Nov 8, 2023 CNFR R FINAL REFUSAL WRITTEN Loading...
Sep 28, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Sep 27, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Sep 27, 2023 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Loading...
May 24, 2023 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
May 24, 2023 GNSL S LETTER OF SUSPENSION E-MAILED Loading...
May 24, 2023 CNSL R SUSPENSION LETTER WRITTEN Loading...
Apr 19, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Apr 19, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Apr 19, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Apr 3, 2023 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Loading...
Apr 3, 2023 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Loading...
Jan 5, 2023 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jan 5, 2023 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jan 5, 2023 CNRT R NON-FINAL ACTION WRITTEN Loading...
Dec 17, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Mar 11, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Mar 10, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
A full line of medicated and pharmaceutical preparations, namely, pharmaceutical preparations and substances for use in the prevention, treatment and management of cancer, autoimmune diseases, immunological deficiency syndromes in the nature of autoimmune diseases, and critical illnesses in the nature of immune system related diseases and disorders for use in connection with humans
First Use Anywhere: Nov 19, 2019
First Use in Commerce: Nov 19, 2019
Class 044
Providing healthcare and medical information; Providing information in the fields of Oncology, Immunology, and Critical Care
First Use Anywhere: Nov 19, 2019
First Use in Commerce: Nov 19, 2019

Classification

International Classes
005 044

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"BIOPHARMA"